| Aktie | Ticker | Breite | GCS | 2026/Q1 | |||
|---|---|---|---|---|---|---|---|
| Investment ($) | QoQ ($) | QoQ (%) | Anz. Fonds | ||||
| 677.093.705 $ | +401.144.052 $ | +214,0 % | 10 | ||||
| Maze Therapeutics, Inc. | MAZE | → 0 | Schwach | 122.983.582 $ | +72.389.331 $ | +143,1 % | 1 |
| Rapport Therapeutics, Inc. | RAPP | → 0 | Neutral | 116.672.212 $ | +74.239.174 $ | +175,0 % | 1 |
| Vir Biotechnology, Inc. | VIR | → 0 | Neutral | 115.733.300 $ | +50.633.318 $ | +77,8 % | 1 |
| Erasca, Inc. | ERAS | → 0 | Neutral | 114.741.392 $ | +100.645.561 $ | +714,0 % | 1 |
| Beam Therapeutics Inc. | BEAM | → 0 | Neutral | 108.191.346 $ | +30.963.701 $ | +40,1 % | 1 |
| Lyell Immunopharma, Inc. | LYEL | → 0 | Neutral | 65.138.070 $ | +49.025.459 $ | +304,3 % | 1 |
| Generate Biomedicines, Inc. | GENB | → 0 | Stark | 24.305.325 $ | +24.305.325 $ | 1 | |
| 10x Genomics, Inc. | TXG | → 0 | Neutral | 4.624.616 $ | +4.624.616 $ | 1 | |
| Gossamer Bio, Inc. | GOSS | → 0 | Schwach | 2.646.368 $ | -7.262.409 $ | -73,3 % | 1 |
| Q32 Bio Inc. | QTTB | → 0 | Neutral | 2.057.494 $ | +1.579.976 $ | +330,9 % | 1 |
| 677.093.705 $ | +401.144.052 $ | +214,0 % | 10 | ||||